Oxurion Announces Extraordinary and Annual Shareholders’ Meetings
April 01 2022 - 1:00PM
Oxurion Announces Extraordinary and Annual Shareholders’ Meetings
Leuven,
Belgium, Boston, MA, US -
April 1,
2022 –
07.00
PM CET – Oxurion
NV (Euronext Brussels: OXUR) (the “Company” or “Oxurion”), a
biopharmaceutical company developing next generation standard of
care ophthalmic therapies, with clinical stage assets in vascular
retinal disorders, announces extraordinary and annual shareholders’
meetings to be held on Tuesday 3 May 2022 at 10:00 AM (CET) and
2:00 PM (CET), respectively.
The convening notice and other documents
pertaining to the shareholders’ meetings can be consulted on our
website Oxurion/shareholders.
About Oxurion
Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company
developing next generation standard of care ophthalmic therapies,
which are designed to better preserve vision in patients with
retinal vascular disorders including diabetic macular edema (DME),
the leading cause of vision loss in diabetic patients worldwide as
well as other conditions, including wet age-related macular
degeneration (wet AMD) and macular edema following retinal vein
occlusion (ME-RVO). Oxurion is aiming to build a leading global
franchise in the treatment of retinal vascular disorders based on
the successful development of its two novel therapeutics. THR-149
is a potent plasma kallikrein inhibitor being developed as a
potential new standard of care for the up to 50% of DME patients
showing suboptimal response to anti-VEGF therapy. THR-687 is a
highly selective pan-RGD integrin antagonist that is being
developed as a potential first line therapy for DME patients as
well as wet AMD and potentially ME-RVO. Oxurion is headquartered in
Leuven, Belgium, with corporate operations in Boston, MA. More
information is available at www.oxurion.com.
For more information, please contact:
Oxurion NVTom GraneyChief Executive OfficerTel:
+32 16 75 13 10tom.graney@oxurion.com Michaël
DillenChief Business OfficerTel: +32 479 783
583michael.dillen@oxurion.com |
EUMEDiSTRAVA ConsultingDavid
Dible/ Sylvie Berrebi/Frazer HallTel: +44 20 7638
9571oxurion@medistrava.com USWestwicke,
an ICR CompanyChristopher BrinzeyTel: +1 617 835
9304chris.brinzey@westwicke.com |
Oxurion Nv (LSE:0G99)
Historical Stock Chart
From Aug 2024 to Sep 2024
Oxurion Nv (LSE:0G99)
Historical Stock Chart
From Sep 2023 to Sep 2024